

BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

CIN: L24233MP1985PLC002709

Registered Office: 11/12, Sector E Sanwer Road, Indore-452015 (M.P.)

Tel. 0731-2723016; Email id- bcplcompliance@gmail.com;

Website- www.biofilgroup.net; Fax: 0731-2723017

Date: 30th January, 2024

To,

The Secretary,

Corporate Relationship Department

National Stock Exchange of India Limited

Bandra Kurla Complex, Mumbai

To,

The Secretary,

Corporate Relationship Department

BSE Limited

Phiroze Jeejee bhoy Towers,

Dalal Street, Mumbai-400001

Subject: Intimation for meeting of Board of Directors (Serial No.04/2023-24) of the Company scheduled to be held on Tuesday, 06th February, 2024 pursuant to the Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Reference: Biofil Chemicals and Pharmaceuticals Limited (BSE SCRIP CODE: 524396; NSE SYMBOL: BIOFILCHEM; ISIN: INE829A01014)

Dear Sir/Madam,

With reference to above captioned subject and in terms of Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the meeting of the Board of Directors of the Company is scheduled to be held on **Tuesday, 06th February, 2024** at Registered Office of the Company to transact the following matters:

1. To consider and approve un-audited Financial Results for the quarter as well as nine months ended on 31st December, 2023 along with Limited Review Report thereon.
2. To consider other routine matters with the permission of Chair.

Further, we are submitting the above said information in XBRL mode (Excel Template provided by Exchange) along with the submission in PDF mode within prescribed time limit.

Further, in continuation to earlier disclosure dated 28th December, 2023, pursuant to Company's code of conduct to regulate, monitor and report trading in Company's Securities by Insiders framed under SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended, Trading Window for dealing in the securities of the

Company shall open after 48 hours of declaration of un-audited Financial Results for the quarter and nine months ended December 31, 2023 for all designated persons, their immediate relatives and all connected persons covered under the aforesaid code.

You are requested to please take on record the above said information for your reference and further needful and disseminate on the website of the Exchange.

This is for your information and record.

Thanking you,

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

**SHWETA VERMA
COMPANY SECRETARY & COMPLIANCE OFFICER
M. No. A70184**